Nicholas Lintzeris

8.2k total citations · 1 hit paper
214 papers, 5.5k citations indexed

About

Nicholas Lintzeris is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology and Pharmacology. According to data from OpenAlex, Nicholas Lintzeris has authored 214 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Public Health, Environmental and Occupational Health, 102 papers in Epidemiology and 72 papers in Pharmacology. Recurrent topics in Nicholas Lintzeris's work include Opioid Use Disorder Treatment (126 papers), Substance Abuse Treatment and Outcomes (87 papers) and Pain Management and Opioid Use (51 papers). Nicholas Lintzeris is often cited by papers focused on Opioid Use Disorder Treatment (126 papers), Substance Abuse Treatment and Outcomes (87 papers) and Pain Management and Opioid Use (51 papers). Nicholas Lintzeris collaborates with scholars based in Australia, United Kingdom and United States. Nicholas Lintzeris's co-authors include Suzanne Nielsen, Louisa Degenhardt, Briony Larance, Raimondo Bruno, Adrian Dunlop, Iain S. McGregor, Gabrielle Campbell, Paul Haber, Milton Cohen and John Strang and has published in prestigious journals such as The Lancet, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Nicholas Lintzeris

202 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic

2020 202 citations Adrian Dunlop, Michelle Hall et al. profile →

Peers

Countries citing papers authored by Nicholas Lintzeris

Since Specialization

Citations

This map shows the geographic impact of Nicholas Lintzeris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Lintzeris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Lintzeris more than expected).

Fields of papers citing papers by Nicholas Lintzeris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Lintzeris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Lintzeris. The network helps show where Nicholas Lintzeris may publish in the future.

Co-authorship network of co-authors of Nicholas Lintzeris

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Lintzeris. A scholar is included among the top collaborators of Nicholas Lintzeris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Lintzeris. Nicholas Lintzeris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings 2025 ·Drug and Alcohol Review ·Bethany White, (unknown), Paul Haber, (unknown), (unknown), Nicholas Lintzeris, Adrian Dunlop	1
2	Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial 2024 ·Addiction ·Nadine Ezard, (unknown), Krista J. Siefried, Robert Ali, Adrian Dunlop, Rebecca McKetin, Raimondo Bruno, Andrew Carr, James Ward, Michael Farrell, (unknown), Paul Haber, Dan I. Lubman, Mark W. Donoghoe, (unknown), Amanda Baker, Michelle Hall, Shalini Arunogiri, Nicholas Lintzeris, (unknown)	2
3	Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey 2023 ·SHILAP Revista de lepidopterología ·Thomas R. Arkell, Sarah V. Abelev, Llewellyn Mills, Anastasia Suraev, Jonathon C. Arnold, Nicholas Lintzeris, Iain S. McGregor	4
4	Understanding the research capacity of alcohol and other drugs services in New South Wales, Australia 2023 ·Drug and Alcohol Review ·(unknown), (unknown), Joanne Ross, (unknown), (unknown), Carolyn Day, Rachel Deacon, Adrian Dunlop, Nicholas Lintzeris	0
5	A systematic review on the effect of routine outcome monitoring and feedback on client outcomes in alcohol and other drug treatment 2023 ·Drug and Alcohol Review ·(unknown), Llewellyn Mills, (unknown), Nicholas Lintzeris	4
6	Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019 2022 ·Drug and Alcohol Review ·Emma Black, (unknown), Rachel Deacon, Nadine Ezard, Llewellyn Mills, Adrian Dunlop, Mark Montebello, David W. Reid, (unknown), Raimondo Bruno, Anthony Shakeshaft, Krista J. Siefried, Michael Farrell, Jennifer Holmes, Nicholas Lintzeris	2
7	The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions 2022 ·Drug and Alcohol Review ·Lauren A. Monds, María Carmen Bravo, Llewellyn Mills, (unknown), (unknown), William R. Wood, Mary Harrod, Phillip Read, Suzanne Nielsen, Paul Dietze, Simon Lenton, (unknown), Nicholas Lintzeris	0
8	Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition 2022 ·Drug and Alcohol Review ·Llewellyn Mills, Nicholas Lintzeris, (unknown), Jonathon C. Arnold, Iain S. McGregor	18
9	Overdose and take‐home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with ‘take‐home naloxone’ in emergency departments 2022 ·Emergency Medicine Australasia ·Eleanor Black, Lauren A. Monds, Betty S. Chan, Jonathan Brett, Jennie Hutton, (unknown), Jonathan Penm, (unknown), (unknown), Apo Demirkol, Nicholas Lintzeris	7
10	Opioid agonist treatment and patient outcomes during the COVID‐19 pandemic in south east Sydney, Australia 2021 ·Drug and Alcohol Review ·Nicholas Lintzeris, Rachel Deacon, (unknown), (unknown), Llewellyn Mills, (unknown), (unknown), (unknown), (unknown), (unknown), Apo Demirkol, (unknown), (unknown)	28
11	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials 2021 ·Addiction Biology ·Thomas R. Arkell, Richard C. Kevin, Frederick Vinckenbosch, Nicholas Lintzeris, Eef L. Theunissen, Johannes G. Ramaekers, Iain S. McGregor	24
12	Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions 2021 ·Drug and Alcohol Review ·(unknown), Llewellyn Mills, Rachel Deacon, Raimondo Bruno, Adrian Dunlop, Jennifer Holmes, (unknown), Anthony Shakeshaft, Michael Farrell, Nicholas Lintzeris	6
13	Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations 2020 ·Drug and Alcohol Review ·Rachel Deacon, (unknown), Jennifer Holmes, Adrian Dunlop, Raimondo Bruno, Llewellyn Mills, Robert J. Graham, Nicholas Lintzeris	15
14	Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence 2020 ·Drug and Alcohol Review ·Llewellyn Mills, Nicholas Lintzeris, Raimondo Bruno, Mark Montebello, Adrian Dunlop, Rachel Deacon, Jan Copeland, Meryem Jefferies, (unknown), (unknown)	8
15	Detection of Δ⁹ THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices 2019 ·Drug Testing and Analysis ·Thomas R. Arkell, Richard C. Kevin, Jordyn Stuart, Nicholas Lintzeris, Paul Haber, Johannes G. Ramaekers, Iain S. McGregor	32
16	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence 2018 ·Drug and Alcohol Review ·Suzanne Nielsen, Nicholas Lintzeris, Bridin Murnion, Louisa Degenhardt, Raimondo Bruno, Paul Haber, Jennifer Johnson, Mark Hardy, (unknown), (unknown), Adrian Dunlop, Apo Demirkol, (unknown), Nghi Phung, (unknown), Briony Larance	5
17	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper‐resistant formulation of controlled‐release oxycodone 2015 ·Pharmacoepidemiology and Drug Safety ·Amy Peacock, Louisa Degenhardt, Briony Larance, Elena Cama, Nicholas Lintzeris, Robert Ali, Raimondo Bruno	4
18	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization 2014 ·Pain Medicine ·Suzanne Nielsen, Nicholas Lintzeris, Raimondo Bruno, Gabrielle Campbell, Briony Larance, Wayne Hall, Bianca Hoban, Milton Cohen, Louisa Degenhardt	92
19	Medicinal drug use and driving 2013 ·(unknown), R W Chapman, Raimondo Bruno, (unknown), Paul Haber, Nicholas Lintzeris	1
20	An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners 2012 ·Pain Medicine ·(unknown), Parker Magin, Janet Dunbabin, Christopher Oldmeadow, (unknown), Nicholas Lintzeris, John Attia, Susan Goode, Adrian Dunlop	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact